Cargando…

The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11

SARS-CoV-2, the virus behind the COVID-19 pandemic, has changed over time to the extent that the current virus is substantially different from what originally led to the pandemic in 2019–2020. Viral variants have modified the severity and transmissibility of the disease and continue do so. How much...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolbert, William D., Chen, Yaozong, Sun, Lulu, Benlarbi, Mehdi, Ding, Shilei, Manickam, Rohini, Pangaro, Emily, Nguyen, Dung N., Gottumukkala, Suneetha, Côté, Marceline, Gonzalez, Frank J., Finzi, Andrés, Tehrani, Zahra R., Sajadi, Mohammad M., Pazgier, Marzena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272436/
https://www.ncbi.nlm.nih.gov/pubmed/37334379
http://dx.doi.org/10.3389/fimmu.2023.1178355
_version_ 1785059494095486976
author Tolbert, William D.
Chen, Yaozong
Sun, Lulu
Benlarbi, Mehdi
Ding, Shilei
Manickam, Rohini
Pangaro, Emily
Nguyen, Dung N.
Gottumukkala, Suneetha
Côté, Marceline
Gonzalez, Frank J.
Finzi, Andrés
Tehrani, Zahra R.
Sajadi, Mohammad M.
Pazgier, Marzena
author_facet Tolbert, William D.
Chen, Yaozong
Sun, Lulu
Benlarbi, Mehdi
Ding, Shilei
Manickam, Rohini
Pangaro, Emily
Nguyen, Dung N.
Gottumukkala, Suneetha
Côté, Marceline
Gonzalez, Frank J.
Finzi, Andrés
Tehrani, Zahra R.
Sajadi, Mohammad M.
Pazgier, Marzena
author_sort Tolbert, William D.
collection PubMed
description SARS-CoV-2, the virus behind the COVID-19 pandemic, has changed over time to the extent that the current virus is substantially different from what originally led to the pandemic in 2019–2020. Viral variants have modified the severity and transmissibility of the disease and continue do so. How much of this change is due to viral fitness versus a response to immune pressure is hard to define. One class of antibodies that continues to afford some level of protection from emerging variants are those that closely overlap the binding site for angiotensin-converting enzyme 2 (ACE2) on the receptor binding domain (RBD). Some members of this class that were identified early in the course of the pandemic arose from the V(H) 3-53 germline gene (IGHV3-53*01) and had short heavy chain complementarity-determining region 3s (CDR H3s). Here, we describe the molecular basis of the SARS-CoV-2 RBD recognition by the anti-RBD monoclonal antibody CoV11 isolated early in the COVID-19 pandemic and show how its unique mode of binding the RBD determines its neutralization breadth. CoV11 utilizes a heavy chain V(H) 3-53 and a light chain V(K) 3-20 germline sequence to bind to the RBD. Two of CoV11’s four heavy chain changes from the V(H) 3-53 germline sequence, [Formula: see text] to Ile and [Formula: see text] to Arg, and some unique features in its CDR H3 increase its affinity to the RBD, while the four light chain changes from the V(K) 3-20 germline sequence sit outside of the RBD binding site. Antibodies of this type can retain significant affinity and neutralization potency against variants of concern (VOCs) that have diverged significantly from original virus lineage such as the prevalent omicron variant. We also discuss the mechanism by which V(H) 3-53 encoded antibodies recognize spike antigen and show how minimal changes to their sequence, their choice of light chain, and their mode of binding influence their affinity and impact their neutralization breadth.
format Online
Article
Text
id pubmed-10272436
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102724362023-06-17 The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11 Tolbert, William D. Chen, Yaozong Sun, Lulu Benlarbi, Mehdi Ding, Shilei Manickam, Rohini Pangaro, Emily Nguyen, Dung N. Gottumukkala, Suneetha Côté, Marceline Gonzalez, Frank J. Finzi, Andrés Tehrani, Zahra R. Sajadi, Mohammad M. Pazgier, Marzena Front Immunol Immunology SARS-CoV-2, the virus behind the COVID-19 pandemic, has changed over time to the extent that the current virus is substantially different from what originally led to the pandemic in 2019–2020. Viral variants have modified the severity and transmissibility of the disease and continue do so. How much of this change is due to viral fitness versus a response to immune pressure is hard to define. One class of antibodies that continues to afford some level of protection from emerging variants are those that closely overlap the binding site for angiotensin-converting enzyme 2 (ACE2) on the receptor binding domain (RBD). Some members of this class that were identified early in the course of the pandemic arose from the V(H) 3-53 germline gene (IGHV3-53*01) and had short heavy chain complementarity-determining region 3s (CDR H3s). Here, we describe the molecular basis of the SARS-CoV-2 RBD recognition by the anti-RBD monoclonal antibody CoV11 isolated early in the COVID-19 pandemic and show how its unique mode of binding the RBD determines its neutralization breadth. CoV11 utilizes a heavy chain V(H) 3-53 and a light chain V(K) 3-20 germline sequence to bind to the RBD. Two of CoV11’s four heavy chain changes from the V(H) 3-53 germline sequence, [Formula: see text] to Ile and [Formula: see text] to Arg, and some unique features in its CDR H3 increase its affinity to the RBD, while the four light chain changes from the V(K) 3-20 germline sequence sit outside of the RBD binding site. Antibodies of this type can retain significant affinity and neutralization potency against variants of concern (VOCs) that have diverged significantly from original virus lineage such as the prevalent omicron variant. We also discuss the mechanism by which V(H) 3-53 encoded antibodies recognize spike antigen and show how minimal changes to their sequence, their choice of light chain, and their mode of binding influence their affinity and impact their neutralization breadth. Frontiers Media S.A. 2023-06-02 /pmc/articles/PMC10272436/ /pubmed/37334379 http://dx.doi.org/10.3389/fimmu.2023.1178355 Text en Copyright © 2023 Tolbert, Chen, Sun, Benlarbi, Ding, Manickam, Pangaro, Nguyen, Gottumukkala, Côté, Gonzalez, Finzi, Tehrani, Sajadi and Pazgier https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tolbert, William D.
Chen, Yaozong
Sun, Lulu
Benlarbi, Mehdi
Ding, Shilei
Manickam, Rohini
Pangaro, Emily
Nguyen, Dung N.
Gottumukkala, Suneetha
Côté, Marceline
Gonzalez, Frank J.
Finzi, Andrés
Tehrani, Zahra R.
Sajadi, Mohammad M.
Pazgier, Marzena
The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
title The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
title_full The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
title_fullStr The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
title_full_unstemmed The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
title_short The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
title_sort molecular basis of the neutralization breadth of the rbd-specific antibody cov11
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272436/
https://www.ncbi.nlm.nih.gov/pubmed/37334379
http://dx.doi.org/10.3389/fimmu.2023.1178355
work_keys_str_mv AT tolbertwilliamd themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT chenyaozong themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT sunlulu themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT benlarbimehdi themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT dingshilei themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT manickamrohini themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT pangaroemily themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT nguyendungn themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT gottumukkalasuneetha themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT cotemarceline themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT gonzalezfrankj themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT finziandres themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT tehranizahrar themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT sajadimohammadm themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT pazgiermarzena themolecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT tolbertwilliamd molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT chenyaozong molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT sunlulu molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT benlarbimehdi molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT dingshilei molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT manickamrohini molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT pangaroemily molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT nguyendungn molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT gottumukkalasuneetha molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT cotemarceline molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT gonzalezfrankj molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT finziandres molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT tehranizahrar molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT sajadimohammadm molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11
AT pazgiermarzena molecularbasisoftheneutralizationbreadthoftherbdspecificantibodycov11